Baker BROS. Advisors LP Sells 12,586 Shares of argenex SE $ARGX

Baker BROS. Advisors LP decreased its position in argenex SE (NASDAQ:ARGX) by 33.3% during the fourth quarter, HoldingsChannel.com reports. The firm owned 25,174 shares of the company’s stock after selling 12,586 shares during the quarter. Baker BROS. Advisors LP’s holdings in argenex were worth $21,170,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Capital World Investors boosted its stake in argenex by 0.4% in the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after purchasing an additional 8,422 shares in the last quarter. M&T Bank Corp boosted its stake in argenex by 20,977.7% in the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares in the last quarter. Wellington Management Group LLP boosted its stake in argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares in the last quarter. Morgan Stanley boosted its stake in argenex by 19.2% in the 4th quarter. Morgan Stanley now owns 518,852 shares of the company’s stock worth $436,331,000 after purchasing an additional 83,746 shares in the last quarter. Finally, Sands Capital Management LLC boosted its stake in argenex by 2,046.6% in the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after purchasing an additional 340,245 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ARGX shares. Royal Bank Of Canada dropped their price target on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research note on Friday, February 27th. Wedbush reissued an “outperform” rating and issued a $1,000.00 target price on shares of argenex in a research report on Thursday, June 11th. Guggenheim boosted their target price on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Finally, HC Wainwright boosted their target price on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, argenex currently has an average rating of “Moderate Buy” and a consensus price target of $1,019.50.

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $892.26 on Thursday. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The business has a 50-day simple moving average of $820.36 and a two-hundred day simple moving average of $810.81. The firm has a market cap of $55.49 billion, a price-to-earnings ratio of 39.73, a price-to-earnings-growth ratio of 1.34 and a beta of 0.47.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The business had revenue of $1.31 billion during the quarter. As a group, research analysts predict that argenex SE will post 26.19 earnings per share for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.